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ﬁgure 1.

Resistance pattern of P. aeruginosa to last-resort antibiotics.

notorious superbugs. Unless we continue to search fervently
for solutions to this problem, we will soon face a time when
mortality is caused by common infections.
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To the Editor—We are currently facing a crisis in healthcare: an
increase in antibiotic-resistant infections coincident with a
decrease in antimicrobials available to effectively and safely
treat these pathogens.1 Over the past decade, antibiotic development has lagged, failing to keep pace with growing bacterial
resistance.2 There are both economic and scientiﬁc reasons for
this slowdown in antibiotic development.3 From the economic
perspective, it is difﬁcult for pharmaceutical companies to
generate a substantial proﬁt from antibiotics.1,2 Unlike agents
that are administered for chronic conditions, antibiotics are
prescribed to treat acute conditions and thus used for a limited
period. Furthermore, newer agents are generally targeted to
antimicrobial-resistant organisms and thus have limited
applications. From a scientiﬁc perspective, new antimicrobial
targets of action have been elusive and agents that have tried to
exploit new targets have had unacceptable toxicity.
In an attempt to spur antibiotic development, recent legislative efforts have focused on economic incentives for antibiotic
research and development, including legislation to reduce
pharmaceutical research and development costs through tax
incentives.4,5 The current legislative efforts tackle only one part
of the problem: the current ﬁnancial disincentives that restrict
development of antibiotics for resistant organisms. A complementary approach emphasizing the judicious use of our
existing antibiotic supply is also needed. Creating more antibiotics will provide an immediate beneﬁt to patients infected
with highly resistant organisms. With fewer antibiotics available
to these patients, this is an absolute necessity. However, focusing
only on new antibiotic development has the potential to distract
us from complementary approaches essential for a long-term
solution to this problem. In addition to increasing antibiotic
development, we also need to preserve our existing antimicrobial
agents and control antibiotic overuse. Strengthening antimicrobial stewardship program (ASP) initiatives will provide this
much needed oversight.
For medications other than antibiotics, treatment decisions
impact a single patient. Although nonantibiotic medications
can produce adverse effects or be ineffective in that patient, the
agents remain effective and available for other patients. In
contrast, antibiotic prescribing for one patient can induce
resistance and thus limit the effectiveness of that agent in other
patients. In recognition of both individual patient and societal
paradigms, ASPs have been developed to provide oversight of
antibiotic prescribing by individual providers.6 Antimicrobial
stewardship, at its core, emphasizes the judicious use of antibiotics. Stewardship involves a coordinated, interdisciplinary
approach to optimize antibiotic selection, dose, duration, and
route of administration.6 ASPs improve patient outcomes,
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reduce costs, and can reduce antimicrobial resistance.6–8 For
individual patients, the goal of stewardship is to achieve the
best possible clinical outcome while minimizing adverse drug
events and antibiotic toxicity. On the societal level, ASPs seek
to reduce the emergence of antimicrobial-resistant organisms
and reduce healthcare costs.9 Thus, ASPs balance the needs of
individual patients with the long-term viability of existing
antimicrobial agents.
Fortunately, there is a growing awareness among the
healthcare community and the public about antibiotic
resistance and antibiotic overuse in both healthcare and
agricultural settings. The White House Commission emphasized that judicious antibiotic use is essential to combat the rise
in antibiotic resistance. Two recent legislative efforts, the
Preventing Antibiotic Resistance Act of 2013 (S1256) and the
Preservation of Antibiotics for Medical Treatment Act of 2013
(HR 1150), attempt to limit antibiotic use in the livestock
industry and direct the US Food and Drug Administration to
restrict antibiotics important for human health from being
used in livestock without a clear medical reason to use such
antibiotics in speciﬁc animals. The human healthcare
community applauds these efforts.
Less attention has been paid to the ﬁnancial burden of
antibiotics on patients, which is not addressed by efforts to
subsidize drug development. A new antibiotic will be expensive.
The cost of development, the limited use of new agents, and the
short patent period make it difﬁcult for a pharmaceutical
company to recoup their research and development costs on
new antibiotics. This cost may be necessary as an incentive for
driving innovation.10 Off-label prescribing could occur and
would be proﬁtable but it would also accelerate the emergence
of resistance. As stated in McKellar and Fendrick’s economic
analysis on antibiotic development, drug development therefore “must be coupled with antimicrobial stewardship to
protect against overutilization and reduce selective pressure for
resistance.”10(pS106) We applaud that the recent legislation
anticipates the potential for off-target use of new agents and
monitors antibiotic use to ensure that taxpayer-subsidized drug
development is reserved for highly resistant organisms. New
drugs will be expensive, but we owe our patients an open and
informed discussion of the potential impact of recent legislative
efforts on healthcare costs.
In summary, although recent drug development efforts are
necessary and an important step in the treatment of patients
with antibiotic-resistant infections, simultaneous efforts should
focus on improving and strengthening antibiotic stewardship.
Using both approaches will provide a longer-term solution to
the dilemma of antibiotic resistance in healthcare. We suggest
that additional legislative or regulatory approaches are needed to
support and fund implementation of ASPs and to monitor
antimicrobial use across the continuum of healthcare. We further suggest that incentivizing providers to use antibiotics
appropriately and furthering educational efforts for the public
regarding judicious antibiotic use will preserve the activity of
both existing and new antibiotics while reducing antimicrobial

resistance and costs. The “build more antibiotics approach,”
while clearly necessary for highly resistant infections, if used
alone, will not provide a sustainable solution.
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